Predictors of Cladribine Effectiveness and Safety in Multiple Sclerosis: A Real-World, Multicenter, 2-Year Follow-Up Study.

Indeed, differences in relapse rates between cladribine treatment groups and placebo demonstrated a positive trend as early as 4 weeks, with differences more marked and accompanied by non-overlapping confidence intervals after 24 weeks [ 18 , 19 ].

also in 11,005 other papers